NASDAQ:TFFP - TFF Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.25
  • Forecasted Upside: 172.42 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.37
▼ -0.58 (-5.30%)
1 month | 3 months | 12 months
Get New TFF Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TFFP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TFFP

Average Price Target: $28.25
▲ +172.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for TFF Pharmaceuticals in the last 3 months. The average price target is $28.25, with a high forecast of $37.00 and a low forecast of $18.00. The average price target represents a 172.42% upside from the last price of $10.37.

Buy

The current consensus among 4 polled investment analysts is to buy stock in TFF Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021B. RileyLower Price TargetBuy$36.00 ➝ $31.00High
3/5/2021HC WainwrightBoost Price TargetBuy$31.00 ➝ $37.00High
3/4/2021Roth CapitalBoost Price TargetBuy$23.00 ➝ $27.00High
2/22/2021HC WainwrightReiterated RatingBuy$31.00High
2/8/2021HC WainwrightInitiated CoverageBuy$31.00Low
2/1/2021B. RileyReiterated RatingBuy$36.00Low
1/15/2021B. RileyReiterated RatingBuy$36.00High
12/7/2020B. RileyInitiated CoverageBuy$36.00Medium
11/6/2020Maxim GroupReiterated RatingBuy$18.00Low
10/15/2020Roth CapitalBoost Price TargetBuy$18.00 ➝ $23.00High
9/16/2020Maxim GroupReiterated RatingBuy$18.00Low
8/17/2020Maxim GroupBoost Price TargetPositive ➝ Buy$12.00 ➝ $18.00High
8/14/2020Roth CapitalBoost Price TargetBuy$15.00 ➝ $18.00High
7/30/2020Maxim GroupReiterated RatingBuy$12.00High
7/8/2020Maxim GroupInitiated CoverageBuy$12.00Medium
3/27/2020Roth CapitalReiterated RatingBuyLow
2/27/2020Roth CapitalInitiated CoverageBuy$15.00Low
(Data available from 6/20/2016 forward)
TFF Pharmaceuticals logo
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Read More

Today's Range

Now: $10.37
Low: $10.29
High: $10.90

50 Day Range

MA: $10.81
Low: $8.48
High: $12.67

52 Week Range

Now: $10.37
Low: $5.38
High: $21.14

Volume

363,679 shs

Average Volume

320,886 shs

Market Capitalization

$263.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Frequently Asked Questions

What sell-side analysts currently cover shares of TFF Pharmaceuticals?

The following Wall Street analysts have issued reports on TFF Pharmaceuticals in the last twelve months: B. Riley, HC Wainwright, Maxim Group, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for TFFP.

What is the current price target for TFF Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for TFF Pharmaceuticals in the last year. Their average twelve-month price target is $28.25, suggesting a possible upside of 172.4%. HC Wainwright has the highest price target set, predicting TFFP will reach $37.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $18.00 for TFF Pharmaceuticals in the next year.
View the latest price targets for TFFP.

What is the current consensus analyst rating for TFF Pharmaceuticals?

TFF Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TFFP will outperform the market and that investors should add to their positions of TFF Pharmaceuticals.
View the latest ratings for TFFP.

What other companies compete with TFF Pharmaceuticals?

How do I contact TFF Pharmaceuticals' investor relations team?

TFF Pharmaceuticals' physical mailing address is 2600 Via Fortuna Suite 360, Austin TX, 78746. The company's listed phone number is 737-802-1973 and its investor relations email address is [email protected] The official website for TFF Pharmaceuticals is www.tffpharma.com.